Pengembangan obat untuk Covid-19 (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pengembangan obat untuk Covid-19" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

15doi.org

2^nd place

4^th place

13nih.gov

4^th place

13^th place

7drugs.com

399^th place

480^th place

4fda.gov

447^th place

792^nd place

4web.archive.org

1^st place

3sciencemag.org

857^th place

574^th place

3who.int

195^th place

203^rd place

2biorender.com

low place

2statnews.com

8,771^st place

low place

2bio.org

low place

9,049^th place

2worldcat.org

5^th place

7^th place

1bioworld.com

low place

1europa.eu

68^th place

182^nd place

1airtable.com

low place

1milkeninstitute.org

low place

1sciencedirect.com

149^th place

229^th place

1inserm.fr

9,568^th place

low place

1independent.co.uk

36^th place

129^th place

1pharmaphorum.com

low place

1digitaltrends.com

1,702^nd place

2,238^th place

1cancernetwork.com

low place

1roche.com

low place

1medlineplus.gov

1,581^st place

2,421^st place

1nature.com

234^th place

238^th place

1un.org

97^th place

71^st place

1cdc.gov

218^th place

205^th place

1cancer.org

3,680^th place

9,092^nd place

1techcrunch.com

187^th place

156^th place

1technologyreview.com

1,943^rd place

2,656^th place

1wired.com

193^rd place

344^th place

1fapesp.br

low place

1dw.com

204^th place

555^th place

1clarin.com

365^th place

1,071^st place

1regeneron.com

low place

1cnbc.com

220^th place

474^th place

1pmlive.com

low place

1lilly.com

low place

1cnet.com

272^nd place

304^th place

1covid19-hpc-consortium.org

low place

1c3.ai

low place

1nytimes.com

7^th place

35^th place

1tomshardware.com

2,976^th place

low place

1foldingathome.org

low place

1worldcommunitygrid.org

low place

1globalnews.ca

985^th place

6,809^th place

1indianexpress.com

60^th place

408^th place

1bloomberg.com

99^th place

159^th place

1clinicaltrials.gov

5,225^th place

low place

airtable.com

"COVID-19 vaccine and treatments tracker (Choose vaccines or treatments tab, apply filters to view select data)". Milken Institute. 2021-03-11. Diakses tanggal 2021-03-13. Ringkasan.

bio.org

"Clinical development success rates: 2006–2015" (PDF). BIO Industry Analysis. June 2016.
"Clinical development success rates: 2006–2015" (PDF). BIO Industry Analysis. June 2016.

biorender.com

"COVID-19 vaccine and therapeutics tracker". BioRender. 2021-03-08. Diakses tanggal 2021-03-13.
"COVID-19 vaccine and therapeutics tracker". BioRender. 2021-03-08. Diakses tanggal 2021-03-13.

bioworld.com

"Biopharma products in development for COVID-19". BioWorld. 2021-03-12. Diakses tanggal 2021-03-13.

bloomberg.com

"Hydroxychloroquine halted in WHO-sponsored COVID-19 trials". Bloomberg. 2020-06-17. Diakses tanggal 2020-06-17.

c3.ai

"C3.ai, Microsoft, and Leading Universities Launch C3.ai Digital Transformation Institute". C3.ai. 2020-03-26. Diakses tanggal 27 April 2020.

cancer.org

"Monoclonal Antibodies and Their Side Effects". www.cancer.org (dalam bahasa Inggris). Diakses tanggal 2021-03-20.

cancernetwork.com

Slater H (26 March 2020). "FDA approves Phase III clinical trial of tocilizumab for COVID-19 pneumonia". Cancer Network, MJH Life Sciences. Diarsipkan dari versi asli tanggal 2020-06-17. Diakses tanggal 28 March 2020.

cdc.gov

"Information for clinicians on therapeutic options for COVID-19 patients". US Centers for Disease Control and Prevention. 21 March 2020. Diakses tanggal 22 March 2020.

clarin.com

"Coronavirus: terapistas rechazaron "fuertemente" el uso de suero equino en pacientes graves" [Coronavirus: medics "strongly" reject use of equine serum in severe patients]. Clarín (dalam bahasa Spanyol). 2021-01-17. Diakses tanggal 2021-01-20.

clinicaltrials.gov

National Institute of Allergy and Infectious Diseases (NIAID) (2020-12-05). "A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults".

cnbc.com

Stankiewicz, Christina Farr,Kevin (2020-10-03). "Here's everything we know about the unapproved antibody drug Trump took to combat coronavirus". CNBC (dalam bahasa Inggris). Diakses tanggal 2021-03-20.

cnet.com

"Sixteen supercomputers tackle coronavirus cures in the US". CNET. ViacomCBS. 2020-03-23. Diakses tanggal 27 April 2020.

covid19-hpc-consortium.org

"The COVID-19 High Performance Computing Consortium". The COVID-19 High Performance Computing Consortium. 2020. Diarsipkan dari versi asli tanggal 2020-09-23. Diakses tanggal 2020-04-27.

digitaltrends.com

McGrath J (2 April 2020). "All the COVID-19 vaccines and treatments currently in clinical trials". Digital Trends. Diakses tanggal 6 April 2020.

doi.org

Taylor D (2015). "The Pharmaceutical Industry and the Future of Drug Development". Issues in Environmental Science and Technology. Royal Society of Chemistry: 1–33. doi:10.1039/9781782622345-00001. ISBN 978-1-78262-189-8.
Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W (June 2020). "COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics". Human Vaccines & Immunotherapeutics. 16 (6): 1232–1238. doi:10.1080/21645515.2020.1735227 . PMC 7103671 . PMID 32186952.
"Phase II Trials in Drug Development and Adaptive Trial Design". JACC: Basic to Translational Science (dalam bahasa Inggris). 4 (3): 428–437. 2019-06-01. doi:10.1016/j.jacbts.2019.02.005. ISSN 2452-302X. PMC 6609997 . PMID 31312766. Pemeliharaan CS1: Format PMC (link)
Kupferschmidt, Kai; CohenMar. 22, Jon; 2020; Pm, 3:28 (2020-03-22). "WHO launches global megatrial of the four most promising coronavirus treatments". Science | AAAS (dalam bahasa Inggris). doi:10.1126/science.abb8497. Diakses tanggal 2021-03-20.
Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ (June 2020). "A real-time dashboard of clinical trials for COVID-19". The Lancet. Digital Health. 2 (6): e286–e287. doi:10.1016/S2589-7500(20)30086-8. PMC 7195288 . PMID 32363333.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. (May 2020). "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial". Lancet. 395 (10236): 1569–1578. doi:10.1016/S0140-6736(20)31022-9. PMC 7190303 . PMID 32423584.
Harrison C (April 2020). "Coronavirus puts drug repurposing on the fast track". Nature Biotechnology. 38 (4): 379–381. doi:10.1038/d41587-020-00003-1. PMID 32205870.
Li G, De Clercq E (March 2020). "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)". Nature Reviews. Drug Discovery. 19 (3): 149–150. doi:10.1038/d41573-020-00016-0. PMID 32127666.
Kruse RL (31 January 2020). "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China". F1000Research. 9: 72. doi:10.12688/f1000research.22211.1. PMC 7029759 . PMID 32117569.
Levi-Schaffer, Francesca; de Marco, Ario (2021-01-05). "COVID-19 and the revival of passive immunization: Antibody therapy for inhibiting SARS-CoV-2 and preventing host cell infection: IUPHAR review: 31". British Journal of Pharmacology. doi:10.1111/bph.15359. ISSN 1476-5381.
Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. Diakses tanggal 27 March 2020.
Cheng MP, Lee TC, Tan DH, Murthy S (April 2020). "Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic". CMAJ. 192 (15): E405–E407. doi:10.1503/cmaj.200438. PMC 7162442 . PMID 32336678.
Mullard A (April 2020). "Flooded by the torrent: the COVID-19 drug pipeline". Lancet. 395 (10232): 1245–1246. doi:10.1016/S0140-6736(20)30894-1. PMC 7162641 . PMID 32305088.
Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. (February 2018). "Adaptive designs in clinical trials: why use them, and how to run and report them". BMC Medicine. 16 (1): 29. doi:10.1186/s12916-018-1017-7. PMC 5830330 . PMID 29490655.
Van Norman GA (June 2019). "Phase II Trials in Drug Development and Adaptive Trial Design". JACC. Basic to Translational Science. 4 (3): 428–437. doi:10.1016/j.jacbts.2019.02.005. PMC 6609997 . PMID 31312766.

drugs.com

"Remdesivir approval status". Drugs.com. 24 March 2020. Diakses tanggal 6 April 2020.
"Hydroxychloroquine sulfate". Drugs.com. 31 March 2020. Diakses tanggal 5 April 2020.
"Chloroquine phosphate". Drugs.com. 31 March 2020. Diakses tanggal 5 April 2020.
"Fujifilm Announces the Start of a Phase III Clinical Trial of Influenza Antiviral Drug Avigan (favipiravir) on COVID-19 in Japan and Commits to Increasing Production". Drugs.com via Fujifilm Toyama Chemical Co., Ltd. 31 March 2020. Diarsipkan dari versi asli tanggal 2020-07-28. Diakses tanggal 6 April 2020.
"Ritonavir". Drugs.com. 2020. Diakses tanggal 6 April 2020.
"Kevzara". Drugs.com. 7 March 2019. Diakses tanggal 6 April 2020.
"Tocilizumab". Drugs.com. 7 June 2019. Diakses tanggal 6 April 2020.

dw.com

"Argentina aprueba uso de suero equino que reduce en un 45% las muertes por COVID-19" [Argentina approves use of equine serum which reduces COVID-19 deaths by 45%] (dalam bahasa Spanyol). Deutsche Welle. 2021-01-11. Diakses tanggal 2021-01-20.

europa.eu

ema.europa.eu

"Call to pool research resources into large multi-centre, multi-arm clinical trials to generate sound evidence on COVID-19 treatments". European Medicines Agency. 19 March 2020. Diakses tanggal 21 March 2020.

fapesp.br

revistapesquisa.fapesp.br

"Butantan desenvolve soro contra coronavírus" [Butantan develops serum against coronavirus]. Revista Pesquisa Fapesp (dalam bahasa Portugis). 2020-12-14. Diakses tanggal 2021-01-20.

fda.gov

"The Drug Development Process". U.S. Food and Drug Administration (FDA). 4 January 2018. Diakses tanggal 21 March 2020.
"Step 2: Preclinical Research". U.S. Food and Drug Administration (FDA). 4 January 2018. Diakses tanggal 23 March 2020.
Commissioner, Office of the (2020-11-13). "Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19". FDA (dalam bahasa Inggris). Diakses tanggal 2021-03-20.
"Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry" (PDF). U.S. Food and Drug Administration (FDA). 1 November 2019. Diakses tanggal 3 April 2020.

foldingathome.org

"Folding@home takes up the fight against COVID-19 / 2019-nCoV". Folding@home. 27 February 2020. Diakses tanggal 12 March 2020.

globalnews.ca

Maria Cheng, Jamey Keaten (2020-05-25). "WHO pauses hydroxychloroquine coronavirus trial over safety concerns". Global News. The Associated Press. Diakses tanggal 2020-05-27.

independent.co.uk

Gregory A (18 March 2020). "Coronavirus: Japanese anti-viral drug effective in treating patients, Chinese official says". The Independent. Diakses tanggal 19 March 2020.

indianexpress.com

"WHO restarts HCQ trial after Lancet concern over paper that trashed it". indianexpress.com. The Indian Express. 4 June 2020. When contacted, Soumya Swaminathan, chief scientist at WHO, told The Indian Express: Our data safety monitoring board reviewed the mortality data in Solidarity... They did not have concerns related to mortality between HCQ and standard of care. Hence, we have decided to resume the trial.

inserm.fr

presse.inserm.fr

"Launch of a European clinical trial against COVID-19". INSERM. 22 March 2020. Diakses tanggal 5 April 2020. The great strength of this trial is its "adaptive" nature. This means that ineffective experimental treatments can very quickly be dropped and replaced by other molecules that emerge from research efforts. We will therefore be able to make changes in real time, in line with the most recent scientific data, in order to find the best treatment for our patients

lilly.com

investor.lilly.com

"Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19 | Eli Lilly and Company". investor.lilly.com (dalam bahasa Inggris). Diakses tanggal 2021-03-20.

medlineplus.gov

"Dapagliflozin: MedlinePlus Drug Information". medlineplus.gov. 2020-04-20. Diakses tanggal 2020-04-27.

milkeninstitute.org

"COVID-19 vaccine and treatments tracker (Choose vaccines or treatments tab, apply filters to view select data)". Milken Institute. 2021-03-11. Diakses tanggal 2021-03-13. Ringkasan.

nature.com

Harrison C (April 2020). "Coronavirus puts drug repurposing on the fast track". Nature Biotechnology. 38 (4): 379–381. doi:10.1038/d41587-020-00003-1. PMID 32205870.

nih.gov

ncbi.nlm.nih.gov

Strovel J, Sittampalam S, Coussens NP, Hughes M, Inglese J, Kurtz A, et al. (July 1, 2016). "Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies". Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences. PMID 22553881.
Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W (June 2020). "COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics". Human Vaccines & Immunotherapeutics. 16 (6): 1232–1238. doi:10.1080/21645515.2020.1735227 . PMC 7103671 . PMID 32186952.
"Phase II Trials in Drug Development and Adaptive Trial Design". JACC: Basic to Translational Science (dalam bahasa Inggris). 4 (3): 428–437. 2019-06-01. doi:10.1016/j.jacbts.2019.02.005. ISSN 2452-302X. PMC 6609997 . PMID 31312766. Pemeliharaan CS1: Format PMC (link)
Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ (June 2020). "A real-time dashboard of clinical trials for COVID-19". The Lancet. Digital Health. 2 (6): e286–e287. doi:10.1016/S2589-7500(20)30086-8. PMC 7195288 . PMID 32363333.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. (May 2020). "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial". Lancet. 395 (10236): 1569–1578. doi:10.1016/S0140-6736(20)31022-9. PMC 7190303 . PMID 32423584.
Harrison C (April 2020). "Coronavirus puts drug repurposing on the fast track". Nature Biotechnology. 38 (4): 379–381. doi:10.1038/d41587-020-00003-1. PMID 32205870.
Li G, De Clercq E (March 2020). "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)". Nature Reviews. Drug Discovery. 19 (3): 149–150. doi:10.1038/d41573-020-00016-0. PMID 32127666.
Kruse RL (31 January 2020). "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China". F1000Research. 9: 72. doi:10.12688/f1000research.22211.1. PMC 7029759 . PMID 32117569.
Cheng MP, Lee TC, Tan DH, Murthy S (April 2020). "Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic". CMAJ. 192 (15): E405–E407. doi:10.1503/cmaj.200438. PMC 7162442 . PMID 32336678.
Mullard A (April 2020). "Flooded by the torrent: the COVID-19 drug pipeline". Lancet. 395 (10232): 1245–1246. doi:10.1016/S0140-6736(20)30894-1. PMC 7162641 . PMID 32305088.
Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. (February 2018). "Adaptive designs in clinical trials: why use them, and how to run and report them". BMC Medicine. 16 (1): 29. doi:10.1186/s12916-018-1017-7. PMC 5830330 . PMID 29490655.
Van Norman GA (June 2019). "Phase II Trials in Drug Development and Adaptive Trial Design". JACC. Basic to Translational Science. 4 (3): 428–437. doi:10.1016/j.jacbts.2019.02.005. PMC 6609997 . PMID 31312766.

pubmed.ncbi.nlm.nih.gov

Levi-Schaffer, Francesca; de Marco, Ario (2021-01-05). "COVID-19 and the revival of passive immunization: Antibody therapy for inhibiting SARS-CoV-2 and preventing host cell infection: IUPHAR review: 31". British Journal of Pharmacology. doi:10.1111/bph.15359. ISSN 1476-5381.

nytimes.com

"A.I. Versus the Coronavirus". The New York Times. 26 March 2020. Diakses tanggal 27 April 2020.

pharmaphorum.com

Staines R (31 March 2020). "Sanofi begins trial of Kevzara against COVID-19 complications". PharmaPhorum. Diakses tanggal 6 April 2020.

pmlive.com

"UPDATED: Regeneron's COVID-19 antibody cocktail shows 'clear efficacy'". PMLive (dalam bahasa Inggris). 2021-02-26. Diakses tanggal 2021-03-20.

regeneron.com

"Regeneron's COVID-19 Response Efforts". www.regeneron.com. Diakses tanggal 2021-03-20.

roche.com

"Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia". Hoffmann-La Roche. 29 July 2020. Diakses tanggal 2020-08-18.

sciencedirect.com

"Phase II Trials in Drug Development and Adaptive Trial Design". JACC: Basic to Translational Science (dalam bahasa Inggris). 4 (3): 428–437. 2019-06-01. doi:10.1016/j.jacbts.2019.02.005. ISSN 2452-302X. PMC 6609997 . PMID 31312766. Pemeliharaan CS1: Format PMC (link)

sciencemag.org

Kupferschmidt, Kai; CohenMar. 22, Jon; 2020; Pm, 3:28 (2020-03-22). "WHO launches global megatrial of the four most promising coronavirus treatments". Science | AAAS (dalam bahasa Inggris). Diakses tanggal 2021-03-20.
Kupferschmidt, Kai; CohenMar. 22, Jon; 2020; Pm, 3:28 (2020-03-22). "WHO launches global megatrial of the four most promising coronavirus treatments". Science | AAAS (dalam bahasa Inggris). doi:10.1126/science.abb8497. Diakses tanggal 2021-03-20.
Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. Diakses tanggal 27 March 2020.

statnews.com

Fox M (19 Maret 2020). "Drug makers are racing to develop immune therapies for Covid-19. Will they be ready in time?". Stat. Diakses tanggal 21 Maret 2020.
"WHO to launch multinational trial to jumpstart search for coronavirus drugs". STAT. 18 March 2020. Diakses tanggal 28 March 2020.

techcrunch.com

social.techcrunch.com

"FDA now allows treatment of life-threatening COVID-19 cases using blood from patients who have recovered". TechCrunch. Diarsipkan dari versi asli tanggal 2020-10-11. Diakses tanggal 9 April 2020.

technologyreview.com

"Blood plasma taken from covid-19 survivors might help patients fight off the disease". MIT Technology Review.

tomshardware.com

"Help Cure Coronavirus with Your PC's Leftover Processing Power". Tom's Hardware. 3 March 2020. Diakses tanggal 12 March 2020.

un.org

news.un.org

"UN health chief announces global 'solidarity trial' to jumpstart search for COVID-19 treatment". UN News (dalam bahasa Inggris). 2020-03-18. Diakses tanggal 2021-03-20.

web.archive.org

"Fujifilm Announces the Start of a Phase III Clinical Trial of Influenza Antiviral Drug Avigan (favipiravir) on COVID-19 in Japan and Commits to Increasing Production". Drugs.com via Fujifilm Toyama Chemical Co., Ltd. 31 March 2020. Diarsipkan dari versi asli tanggal 2020-07-28. Diakses tanggal 6 April 2020.
Slater H (26 March 2020). "FDA approves Phase III clinical trial of tocilizumab for COVID-19 pneumonia". Cancer Network, MJH Life Sciences. Diarsipkan dari versi asli tanggal 2020-06-17. Diakses tanggal 28 March 2020.
"FDA now allows treatment of life-threatening COVID-19 cases using blood from patients who have recovered". TechCrunch. Diarsipkan dari versi asli tanggal 2020-10-11. Diakses tanggal 9 April 2020.
"The COVID-19 High Performance Computing Consortium". The COVID-19 High Performance Computing Consortium. 2020. Diarsipkan dari versi asli tanggal 2020-09-23. Diakses tanggal 2020-04-27.

who.int

"COVID-19 drug development: Landscape analysis of therapeutics (table)" (PDF). United Nations, World Health Organization. 21 March 2020. Diakses tanggal 29 March 2020.
"'Solidarity' clinical trial for COVID-19 treatment". World Health Organization. 2020-04-27. Diakses tanggal 2020-05-01.
"WHO Director-General's opening remarks at the media briefing on COVID-19". World Health Organization. 2020-05-25. Diakses tanggal 2020-05-27.

wired.com

"Trials of Plasma From Recovered Covid-19 Patients Have Begun". Wired.

worldcat.org

"Phase II Trials in Drug Development and Adaptive Trial Design". JACC: Basic to Translational Science (dalam bahasa Inggris). 4 (3): 428–437. 2019-06-01. doi:10.1016/j.jacbts.2019.02.005. ISSN 2452-302X. PMC 6609997 . PMID 31312766. Pemeliharaan CS1: Format PMC (link)
Levi-Schaffer, Francesca; de Marco, Ario (2021-01-05). "COVID-19 and the revival of passive immunization: Antibody therapy for inhibiting SARS-CoV-2 and preventing host cell infection: IUPHAR review: 31". British Journal of Pharmacology. doi:10.1111/bph.15359. ISSN 1476-5381.

worldcommunitygrid.org

"OpenPandemics – COVID-19". IBM. 2020. Diakses tanggal 18 May 2020.